Lecalpin (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels in the smooth muscle of blood vessels. This inhibition prevents calcium‑mediated contraction, leading to vasodilation, reduced peripheral resistance, and a consequent fall in arterial blood pressure.

The appropriate dose of Lecalpin is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions exactly.

The safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecalpin belongs to the calcium channel blocker class, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. Compared with beta‑blockers or ACE inhibitors, it primarily reduces vascular resistance without significant effects on heart rate or renal function, making it a useful alternative or add‑on therapy.

Lecalpin tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Lecalpin is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, though rare, include angioedema, severe hypotension, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or signs of liver dysfunction.

Lecalpin is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment or those taking contraindicated strong CYP3A4 inhibitors without appropriate medical supervision.